Hypocrellin A against Intrahepatic Cholangiocarcinoma via Multi-Target Inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 Signaling Pathways

Intrahepatic cholangiocarcinoma (ICC) is an aggressive and highly lethal cancer with an increasing incidence worldwide that lacks effective treatment regimens. Hypocrellin A (HA), a natural small compound isolated from S. bambusicola, has multiple biomedical activities, including antitumor activity.